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Abstract
Studies in non-human primates, with simian immunodeficiency virus (SIV) and simian/human immunodeficiency virus (SHIV) have
demonstrated that live-attenuated viral vaccines are highly effective; however these vaccine viruses maintain a low level of pathogenicity.
Lentivirus attenuation associated with deletion of the viral vif gene carries a significantly reduced risk for pathogenicity, while retaining the
potential for virus replication of low magnitude in the host. This report describes a vif-deleted simian immunodeficiency virus (SIV)mac239
provirus that was tested as an attenuated proviral DNA vaccine by inoculation of female rhesus macaques. SIV-specific interferon-γ enzyme-
linked immunospot responses of low magnitude were observed after immunization with plasmid containing the vif-deleted SIV provirus.
However, vaccinated animals displayed strong sustained virus-specific T cell proliferative responses and increasing antiviral antibody titers. These
immune responses suggested either persistent vaccine plasmid expression or low level replication of vif-deleted SIV in the host. Immunized and
unvaccinated macaques received a single high dose vaginal challenge with pathogenic SIVmac251. A transient suppression of challenge virus load
and a greater median survival time was observed for vaccinated animals. However, virus loads for vaccinated and unvaccinated macaques were
comparable by twenty weeks after challenge and overall survival curves for the two groups were not significantly different. Thus, a vif-deleted
SIVmac239 proviral DNA vaccine is immunogenic and capable of inducing a transient suppression of pathogenic challenge virus, despite severe
attenuation of the vaccine virus.
© 2008 Elsevier Inc. All rights reserved.Keywords: SIV; DNA vaccine; vif; ImmunogenicityIntroduction
The incidence of AIDS worldwide is rising, and the need
continues for the development of an effective and safe vaccine
against the human immunodeficiency virus (HIV), with the
primary objective of arresting the spread of the AIDS epidemic.⁎ Corresponding author. 2108 Tupper Hall, Department of Medicine and
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doi:10.1016/j.virol.2008.01.020Studies in non-human primates with simian immunodeficiency
virus (SIV) and simian/human immunodeficiency virus (SHIV)
demonstrated efficacy for live-attenuated virus vaccines based
on non-virulent cloned viral variants or clones engineered with
deletions in viral various accessory genes including nef (Abel
et al., 2003; Almond and Stott, 1999; Daniel et al., 1992;
Lohman et al., 1994). However, subsequent studies revealed the
potential for pathogenicity for live-attenuated SIV vaccine
viruses for both neonatal and adult macaques (Baba et al., 1995,
1999; Hofmann-Lehmann et al., 2003). More recent studies
have revealed vaccine induction of limited protection against
pathogenic SIV or SHIV challenge with protection defined as
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preservation of memory CD4 T cell populations. Vaccine
approaches generating this type of efficacy include multi-gene
DNA expression plasmids boosted with either recombinant viral
vectors encoding viral genes or with cytokine adjuvants (Hokey
andWeiner, 2006; Letvin, 2006; Lori et al., 2006). Nevertheless,
optimization of different components of current vaccine
strategies, or development of additional novel approaches, will
be required to generate a truly effective AIDS vaccine.
Several reports have also shown immunogenicity with
limited efficacy for single modality DNA vaccines that are
based on a replication-defective SIVor SHIV provirus encoding
mutations within reverse transcriptase, integrase, or nucleocap-
sid genes (Akahata et al., 2000; Gorelick et al., 2000; Liu et al.,
2006; Singh et al., 2005; Wang et al., 2000). Similarly, a
previous study in our laboratory revealed some success for a
highly attenuated vif-deleted feline immunodeficiency virus
(FIV) proviral DNA vaccine for inducing protection in cats
against challenge with a wild type FIV, despite the severe
restriction imposed on virus replication by deletion of the viral
vif gene within the vaccine viral DNA (Lockridge et al., 2000).
Although reports describing animal infection studies with vif-
deleted lentiviruses have been limited, all have shown the
absolute requirement for vif for detectable virus replication in
vivo (Desrosiers et al., 1998; Gabuzda et al., 1994; Harmache
et al., 1996; Inoshima et al., 1996; Kristbjornsdottir et al., 2004;
Lockridge et al., 1999). Inoculation with lentviral vif mutants
resulted in infections characterized by undetectable virus loads
in peripheral blood and lymph nodes and by antiviral antibody
responses in some animals that were measurable only by very
sensitive antibody assays. These findings suggested the pos-
sibility that inoculation with a vif-deleted virus or proviral DNA
results in either an abortive infection or a persistent infection
with exceptionally low level replication. Importantly, observa-
tions from in vivo inoculation studies confirmed the severe
attenuation associated with vif-deletion. In addition, mechan-
isms by which HIV-1 and SIV vif promote viral infectivity and
replication in cell culture, were recently characterized by reports
that revealed HIV-1 vif targets cellular cytidine deaminases of
the human APOBEC3 family for proteosomal degradation by
the vif gene product, thereby preventing virion incorporation of
these antiviral cellular proteins (see review) (Cullen, 2006).
These recent studies not only clarified the role of vif in the viral
replication cycle, but also confirmed the critical requirement of
this viral protein for HIV-1 and SIV infectivity and replication.
The use of a vif-deleted provirus, as the basis for a DNA
vaccine for AIDS, holds several potential advantages. Similar to
replication-defective proviral DNA vaccines, a vif-deletion
mutant provides a vector capable of expressing all viral genes,
with the exception of vif, necessary for the assembly of virus
particles. Moreover, virus produced from a vif-deletion mutant
may not be truly defective, but instead may be highly restricted
for replication, allowing for a slightly higher expression of viral
immunogens than that observed with proviruses deleted for
genes absolutely required for virus replication such as reverse
transcriptase. Also, proviral DNA inoculation, in contrast to
inoculation with virus particles, allows direct delivery of theviral genome to host cells for those attenuated viruses of con-
siderably lower infectivity as displayed by vif-deletion mutants.
Lastly, immunization with a vif-deleted provirus plasmid
combines the immunogenicity associated with plasmid DNA
(see reviews) (Giri et al., 2004; Letvin, 2006) and attenuated
virus vaccines. Based on these underlying principles, female
rhesus macaques were immunized with a vif-deleted SIV-
mac239 provirus by DNA inoculation for the present study.
Immunogenicity of this proviral DNAvaccine was examined by
assays for SIV-specific cellular and humoral immune responses
after DNA vaccination. Efficacy of this vif-deleted SIVmac239
proviral DNA vaccine was examined by challenge with path-
ogenic SIVmac251 by the vaginal route. This study revealed
that a vif-deleted SIVmac239 proviral DNA vaccine was immu-
nogenic, especially for virus-specific T cell proliferative re-
sponses, regardless of severe virus attenuation. Furthermore,
immunization with this vif-deletion mutant resulted in restric-
tion of challenge virus replication during the acute stage of
infection with SIVmac251.
Results and discussion
Construction and replication of SIV/CMVΔvif
To enhance expression of the proviral genome, the 5′ LTR of
SIVmac239 was modified by the replacement of the U3
promoter domain with the enhancer region of the human
cytomegalovirus (CMV) immediate early (IE) gene promoter.
The vif-deleted SIVmac239 provirus encoding a 5′ hybrid LTR
(CMV-LTR) is illustrated in Fig. 1A; construction of this clone
utilized a previously described vif-deleted provirus (Zou and
Luciw, 1996). To assess transcriptional activity of the chimeric
LTR, transient expression assays were performed to compare
luciferase reporter plasmids containing the hybrid LTR (pCMV-
LTR/Luc) and wild type SIVmac239 LTR (SIV-LTR/Luc).
Assay for luciferase activity from transfected 293T cells showed
a five-fold increase in activity directed by the hybrid LTR
compared to that of wild type SIV-LTR (data not shown). Based
on these findings and previous reports showing that expression
vectors containing the CMV IE promoter or enhancer domains
exhibit higher levels of expression (Galvin et al., 2000;
Manthorpe et al., 1993), the genome of the SIVmac239Δvif
provirus was modified by replacement of the 5′ LTR with that of
the hybrid CMV-LTR. The provirus plasmid clone with this
hybrid LTR was designated SIV/CMVΔvif and was used as the
vaccine DNA in this study. Virus produced from the vaccine
provirus SIV/CMVΔvif was assayed for replication in cell
types either permissive or nonpermissive for vif-deleted SIVmac
isolates, including SupT1 cells and rhesus peripheral blood
mononuclear cells (PBMC), respectively. Virus production from
PBMC infected with SIV/CMVΔvif virus was severely
restricted although not completely ablated, with SIV p27Gag
concentrations peaking at 3.5 to 3.9 ng per ml of cell culture
supernatant (Fig. 1B). Similarly, SIV/CMVΔvif virus replica-
tion in rhesusMM221 cells (Fig. 1C) was also severely restricted
compared to wild type SIVmac239, although this cell line
appeared slightly more permissive for vif-deleted SIVreplication
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CMVΔvif and wild type SIVmac239 was comparable in SupT1
cells (Fig. 1D). These findings confirmed that virus produced by
plasmid SIV/CMVΔvif replicated in vitro similar to that
previously shown for the progenitor provirus SIVmac239Δvif
(Zou and Luciw, 1996).Cellular immune responses induced by vaccination with SIV/
CMVΔvif proviral DNA
The first objective of this study was to test the immuno-
genicity of the vaccine plasmid SIV/CMVΔvif by intradermal
and intramuscular inoculation of six female rhesus macaques.
An interferon (IFN)-γ enzyme-linked immunospot (ELISPOT)
assay, testing PBMC responses specific to four different SIV
immunogens, revealed variable and relatively low activity at
multiple time points after priming immunization (Fig. 2). This
recombinant vaccinia-based ELISPOT assay was previously
shown to reflect predominantly CD8 responses, as antigen is
presented by the MHC class 1 pathway (Larsson et al., 1999).
Responses were observed predominantly at early time points
including two and six weeks after priming immunization and at
two weeks after the first booster immunization. In addition,
responses were detected in five of the six vaccinated macaques
for at least one of the four immunogens tested. A higher fre-
quency and magnitude of IFN-γ ELISPOT responses specific to
SIV Gag and Nef were measured, whereas responses to Env and
Pol were low or absent. Overall, IFN-γ ELISPOT responses
were weak with the exception of one macaque (27101) who
exhibited moderate to strong responses specific to Gag and Nef,
respectively.
T cell proliferative responses specific to inactivated purified
SIV preparations were robust over most time points tested with
all animals testing positive at two or more time points after
immunization (Fig. 3A). These proliferative responses, pre-
sumably reflecting antigen-specific CD4 Tcell activity, persisted
after priming and the first booster immunizations. Interestingly,
two vaccinated macaques showed stimulation indices (SI) of 45
and 65 at sixteen weeks after the first booster. Proliferative
responses were high and surprisingly sustained, given that
plasma viremia was not detected by real-time PCR assay for SIV
RNA at various time points after proviral plasmid DNA inoc-
ulation (data not shown). Similarly, proviral DNAwas also not
detected in PBMC by a real-time PCR assay for SIV DNA (data
not shown). Although proliferative responses measured by this
particular assay have previously been shown to predominantly
represent proliferating CD4 T cells, proliferation of antigen-
specific CD8 T cells may also be measured by this assay based
on aldrithiol-2 (AT-2)-inactivated SIVmac239 (Frank et al.,
2003; Rutebemberwa et al., 2007). Nevertheless, the difference
in magnitude between IFN-γ ELISPOT and T cell proliferative
responses was considerable and possibly suggested that SIV/Fig. 1. Construction and characterization of the SIV/CMVΔvif vaccine plasmid.
A previously described vif-deleted SIVmac239 provirus (Zou and Luciw, 1996)
was further modified by replacement of the 5′ LTR with a chimeric LTR that
included substitution of a large segment of the U3 domain with the human CMV
immediate early enhancer to create plasmid SIV/CMVΔvif (A). Replication of
virus produced from 293T cells transfected with SIV/CMVΔvif plasmid was
tested by inoculation of macaque PBMC (B) and a macaque T cell line MM221
cells (C) with supernatants harvested from transfected cells. Infected PBMC and
MM221 cell culture supernatants were assayed over time for SIV capsid antigen
as described in Materials and methods. SupT1 cells transfected with SIV/
CMVΔvif plasmid were also maintained in culture and assayed for SIV capsid
antigen production (D).
Fig. 3. SIV-specific T cell proliferative and antiviral antibody responses elicited
by immunization with SIV/CMVΔvif plasmid DNA. Virus-specific T cell
proliferative responses directed to purified inactivated SIV were measured in
PBMC collected from macaques at various time points after vaccination (A).
Values for the highest SI to either 1 or 10 ng of inactivated SIV are shown.
Reciprocal endpoint titers for plasma antibodies against native SIV Env were
measured using a ConA ELISAwith reciprocal log dilution values greater than
50 representing positive titers (see dashed cut line) (B). Antiviral antibodies
were also assayed by a commercial HIV-1/HIV-2 ELISA as described in the text
and are shown as reciprocal endpoint titers (C). Arrows positioned at six and
twenty two weeks after priming immunization denoted time points of booster
vaccine inoculations.
Fig. 2. SIV-specific IFN-γ ELISPOT responses elicited by immunization with
SIV/CMVΔvif plasmid DNA. Virus-specific IFN-γ ELISPOT responses were
assayed on PBMCharvested from animals at various time points after vaccination.
Immune responses to individual SIVmac239 proteins were measured using
recombinant vaccinia viruses expressing either SIV Gag, Env, Nef or Pol with
protocols described in Materials and methods. A value greater than 50 spot-
forming colonies (SFC) per 106 PBMC was considered significant for this assay.
Arrows positioned at six and twenty two weeks after priming immunization
denoted time points of booster vaccine inoculations.
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specific CD4 responses compared to CD8 responses, although
specific cellular phenotypes associated with SIV-specific IFN-γ
ELISPOT and proliferation were not tested. The SIV-specific Tcell proliferative responses observed with inoculation of a vif-
deleted SIV provirus were notable and as high, or greater than,
those observed for macaques infected with wild type SIV-
mac251, and tested by the same assay (Ma et al., 2004).
Induction of strong virus-specific CD4 responses by cloned
attenuated SIVmac239 isolates was reported previously,
although the strength of responses was shown to be reduced
with more severely attenuated SIV isolates compared to nef-
deleted SIVmac239 (Gauduin et al., 1999, 2006). Vaccine-
induced clonal expansion of CD4 T cells without full differ-
entiation into mature CD4 effector cells may provide one
possible explanation for the disproportion of antigen-specific
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immunization with SIV/CMVΔvif DNA (Bayry et al., 2007;
Spörri and Reis e Sousa, 2007). Similarly, recent studies have
reported induction of antigen-specific CD4 T cells without
helper function as a result of CD4 T cell activation by in-
completely matured dendritic cells (Spörri and Reis e Sousa,
2007). A definitive elucidation of mechanisms for the differ-
ential induction of cellular responses by the SIV/CMVΔvif
proviral DNAvaccine will require additional studies focused on
phenotypic and polyfunctional characterization of virus-specific
CD4 and CD8 T cells.
Antiviral antibody responses elicited by immunization with SIV/
CMVΔvif proviral DNA
Low to undetectable antibody responses have been detected in
infection studies with vif-deleted lentiviruses (Desrosiers et al.,
1998; Gupta et al., 2007; Harmache et al., 1996; Inoshima et al.,
1996; Lockridge et al., 2000). Therefore a sensitive concanavalin
A (ConA) ELISA for detection of antibody to native SIV Envwas
used to assay antiviral antibodies after immunization with SIV/
CMVΔvif proviral DNA. Results of the ConA ELISA revealed
that only one animal was positive for Env antibody at six weeks
after priming immunization, whereas five of six animals dem-
onstrated either transient, low (1:100) to higher (1:800) antibody
titers at twoweeks after the first booster inoculation (Fig. 3B). Env
antibody titers ranging from 1:800 to 1:3200 were detected for all
six vaccinated macaques by two weeks after the booster
inoculation. Low titer antiviral antibodies were also detected by
commercial HIV-1/HIV-2 antibody ELISA for two vaccinated
macaques after the first booster immunization and for all vaccinees
after the second booster vaccination (Fig. 3C). Although antibody
titers measured for vaccinated macaques by both assays were
considerably lower than those reported for animals infected with
wild type and some attenuated SIVmac isolates, detection of
antibody by the commercial assay was unexpected based on
previous reports of infection studies with vif-deleted lentiviruses
(Desrosiers et al., 1998; Harmache et al., 1996; Inoshima et al.,
1996; Kristbjornsdottir et al., 2004; Lockridge et al., 2000).
However, previous studies of vif-deleted lentiviruses frequently
used a single inoculation of virus particles for infection rather than
multiple proviral DNA inoculations. Therefore, differences in
route and number of inoculations, and the use of a provirus
directed by the hybrid CMV-LTR, may have accounted for the
emergence of increasing antibody titers observed for SIV/
CMVΔvif-immunized macaques in this study. Regardless, these
observations of both higher than expected humoral responses and
sustained SIV-specific T cell proliferative responses suggested
either persistent expression of this vaccine provirus plasmid or
SIVΔvif virus replication of very low magnitude.
Effects of immunization with SIV/CMVΔvif proviral DNA on
peripheral blood virus loads and CD4 T cell concentrations
after vaginal challenge with SIVmac251
The second objective of this study was to test the efficacy of
vif-deleted SIV proviral DNAvaccine against vaginal challengewith the highly pathogenic isolate SIVmac251. All vaccinated
macaques became viremic after vaginal challenge, whereas one
unvaccinated control remained negative for plasma viral RNA
for all time points tested after challenge (Fig. 4A and B).
Although mean plasma virus loads, measured as viral RNA
copies per ml, were lower for vaccinated macaques compared to
unvaccinated controls over the first sixteen weeks after vaginal
challenge, differences in loads between the two groups were not
statistically significant (P=1.2–1.5) during the first eight weeks
post-challenge with analyses including unvaccinated control
macaque (30037) that remained uninfected after challenge.
However, statistical analysis revealed significant differences
between virus loads for the animal groups at two (P=0.026),
four (P=0.004), and eight (P=0.041) weeks after challenge
when this uninfected control animal was excluded from the
analysis (Fig. 4C). By twenty weeks after challenge, mean virus
loads were similar between vaccinated macaques and unvacci-
nated controls. Importantly, three of the five infected animals
within the unvaccinated control group were rapid progressors
and euthanized due to SIV-associated illnesses, including diar-
rhea and weight loss, by sixteen weeks after challenge (Fig. 4B).
In contrast, only one out of six vaccinated and infected animals
was euthanized within this same time period (Fig. 4A). Study
animals were maintained up to 12–14 months after challenge to
determine effects on long-term survival imposed by vaccina-
tion. A Kaplan–Meier survival analysis revealed a difference in
median survival times for vaccinees (fifty one weeks) and
unvaccinated controls (sixteen weeks) (Fig. 4D). Therefore an
enhanced survival rate during the acute phase of infection and a
greater median survival time was observed for vaccinated ani-
mals. However, long-term survival of animals from both groups
were comparable, with two vaccinated and two unvaccinated
animals controlling virus loads to approximately 5×105 RNA
copies per ml of plasma at the termination of the study.
All six vaccinated animals demonstrated a precipitous
decline in the peripheral blood CD4 T cell population within
two weeks after challenge followed by a stabilization of values
for the percentages of this T cell subset (Fig. 5A). The CD4 T
cell decline at two weeks post-challenge produced a significant
difference between mean values for peripheral blood CD4 T cell
percentages in SIV-infected vaccinees and unvaccinated con-
trols (P=0.015) (Fig. 5B). One possible cause for the accel-
erated CD4 T cell depletion upon challenge would be a vaccine-
induced expansion of SIV-specific CD4 T cell population as
indicated by the strong T cell proliferative responses detected
after immunization. This potential mechanism is supported by
findings from other studies showing preferential infection by
HIV-1 for virus-specific CD4 T cell populations (Douek et al.,
2002; Harari et al., 2002). In contrast, unvaccinated viremic
control animals experienced a slower progressive reduction in
CD4 T cell percentages that occurred over an eight week time
period after challenge. Nevertheless, the abrupt reduction in the
peripheral blood CD4 T cell population in vaccinated macaques
was associated with lower peripheral blood virus loads at early
time points post-challenge, when compared to unvaccinated
controls (Fig. 4A). Two of the three unvaccinated animals were
euthanized by sixteen weeks after challenge due to SIV-related
Fig. 4. Plasma virus loads and survival after vaginal challenge of vaccinated and unvaccinated macaques with SIVmac251. Plasma viremia measured as SIV RNA
copies per ml of plasma, was determined after SIVmac251 challenge by a real-time RT-PCR assay for SIV gag RNA for vaccinated (A) and unvaccinated
(B) macaques. Mean values for plasma viral RNA loads over time are shown with standard error bars for vaccinated and unvaccinated control animals (C). The asterisk
(⁎) positioned over values at two, four and eight weeks after challenge indicates a significant difference between vaccinated and unvaccinated controls with P values of
0.026, 0.004, and 0.041 determined by a Mann–Whitney-U test, when the uninfected control animal #30037 is excluded from the analysis. The limit of this real-time
RT-PCR assay for SIV RNA is 100 RNA copies per ml of plasma. A Kaplan–Meier survival curve was generated for vaccinated and unvaccinated animals after
SIVmac251 challenge (D). Median survival time for vaccines was fifty one weeks, whereas median survival for unvaccinated controls was sixteen weeks. However, a
comparison of the two survival curves performed by a log-rank test (GraphPad Prism) revealed no significant difference between the curves for vaccinated and
unvaccinated animals. Note that x-axis scales are uneven to allow better visualization of values for early time points after challenge.
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significant changes in CD4 T cell counts during the acute
phase of challenge infection. Percentages of CD4 T cells were
comparable for both vaccinated and unvaccinated macaques by
four weeks after challenge and remained relatively stable and
similar for those animals in both groups that survived until
termination of the study. The role of major histocompatibility
complex class I haplotypes in control of virus load for macaques
involved in this vaccine study was unclear as all animals were
negative for the rhesus macaque Mamu-A⁎01 allele. Two of the
five vaccinated animals (26349 and 27513) that survived past
the acute phase of SIVmac251 infection, were positive for the
rhesus macaque Mamu-B⁎17 haplotype previously considered
to be predictive of control of SIVmac239 virus load and disease
progression (O'Connor et al., 2003; Yant et al., 2006). However,
findings from a more recent report indicated that inheritance of
this haplotype was not predictive for control of SIVmac239
(Wojcechowskyj et al., 2007). Taken as a whole, these ob-
servations indicated that a single modality vaccine composed of
a vif-deleted SIVmac239 proviral plasmid was capable of
reducing virus loads and mortality during the acute phase of
SIVmac251 infection. However, vaccination was not effective
for inducing sustained control of challenge virus replication orvirus-associated peripheral blood CD4 T cell depletion after
high dose vaginal challenge with pathogenic SIVmac251.
Cellular immune responses after challenge with SIVmac251
For vaccinated macaques, the SIVmac251 challenge induced
a rapid ablation of SIV-specific proliferative responses that had
been moderate to robust just prior to challenge (Fig. 3A). SIV-
specific proliferative responses were entirely suppressed in all
vaccinated animals and also absent in unvaccinated controls at
two weeks after challenge (Fig. 5C). By four weeks after
challenge, low tomoderate proliferative responseswere observed
in two vaccinated and two unvaccinated macaques; this most
likely reflected responses related to virus replication rather than
recall responses associated with vaccination, with the exception
of responses demonstrated by one unvaccinated macaque
(30037). Interestingly, proliferative responses were observed
for this particular control animal that appeared to resist infection
with SIVmac251 based on the absence of a detectable plasma
viremia, antiviral antibody, and SIV-associated disease through-
out the 12 month period of assessment after challenge. Pro-
liferative responses observed for this unvaccinated macaque
substantiated exposure to challenge virus and suggested transient
Fig. 5. Quantitation of CD4 T cell populations and SIV-specific T cell proliferative responses after challenge with SIVmac251. Percentages of CD4 T cells were
calculated for vaccinated and unvaccinated control macaques after SIVmac251 challenge (A). Mean values with standard error for CD4 T cell percentages over time
challenge are shown for both groups of animals (B). The asterisk (⁎) positioned over values at two weeks after challenge indicates a significant difference between
vaccinated and SIV-infected unvaccinated controls with a P value of 0.015 determined by a Mann–Whitney-U test. Virus-specific T cell proliferative responses are
also shown for vaccinated and unvaccinated control animals at two and four weeks after challenge (C). Note that x-axis scales are uneven to allow better visualization
of values for early time points after challenge.
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prevent detection of infection by standard assays used in this
study. Extended follow-up assessment of this animal beyond
12months after challenge and assay of multiple lymphoid tissues
for the presence of SIV proviral DNA at necropsy would be
necessary to determine if this animal suffered an occult infection
as previously described by McChesney et al. (1998) or
completely resisted SIVmac251 infection.
Virus-specific IFN-γ ELISPOT responses were variable but
mostly low to absent after challenge for all vaccinated macaques
(Fig. 6A). The one vaccinated animal (27101) that exhibited
moderate to low ELISPOT responses consistently at time points
both before and after challenge, exhibited declining responses by
twelve weeks after challenge. These declining responses were
coincident with a progressive reduction in peripheral blood CD4
T cells over the sixteen week time period after challenge
(Fig. 5A), at which time the animal was euthanized. Measurable
IFN-γ ELISPOT responses to SIV were not detected in unvac-
cinated animals after challenge (Fig. 6B). In general, IFN-γ
ELISPOT responses observed for vaccinated animals were re-
duced, compared to responses prior to challenge, and were
comparable to those measured for unvaccinated control animals,
with the exception of two vaccinated animals (27101 and 27674).
Weak SIV-specific IFN-γ ELISPOT responses in vaccinated
animals after vaccination and challenge suggested a poor virus-
specific CD8 T cell response was induced by this plasmid
vaccine. The absence of a protective SIV-specific CD8 T cell
response may have augmented the susceptibility of virus-specific
CD4 T cells during the acute phase of infection. Accordingly, anenhanced susceptibility of virus-specific CD4 T cells to infection
as previously described (Brenchley et al., 2004), combined with
insufficient virus-specific CD8 activity could possibly explain
both the abrupt but transient depletion of peripheral blood CD4 T
cells and absolute ablation of previously strong proliferative
responses observed for vaccinated animals during the very early
acute phase of stage of infection. Furthermore, a more recent
study suggested that the preponderance of HIV-1-specific CD4 T
cells in infected patients are of a less mature phenotype and may
be more susceptible to infection and depletion by HIV-1 when
compared to terminally differentiated virus-specific CD4 T cells
(Brenchley et al., 2006). The possibility of induction of
incompletely differentiated virus-specific CD4 T cells by SIV/
CMVΔvif plasmid vaccine may also directly relate to the
disparity observed between SIV-specific T cell proliferative and
IFN-γ ELISPOT responses noted in vaccinated macaques, as
well as the rapid drop in CD4 T cell percentages after challenge.
Future studies characterizing T cell phenotypes represented by
these IFN-γ ELISPOT responses and proliferative responses, as
well as testing for additional cellular immune response functions
including antigen-specific induction of expression of different
cytokines and degranulation markers, will be necessary to
address these issues and to fully characterize SIV/CMVΔvif
DNA-induced cellular responses.
SIV Env antibody responses after challenge with SIVmac251
SIVenvelope-specific antibody titers increased by ten-fold or
more over base-line titers for five of six vaccinated animals by
Fig. 6. IFN-γ ELISPOT responses in animals challenged with SIVmac251. Virus-specific IFN-γ ELISPOT responses were measured for vaccinated (A) and all
unvaccinated control (B) animals for early time points after challenge.
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antibody titers were not detected until four weeks after challenge
in unvaccinated animals, with only three of the six animals
demonstrating SIV Env antibody (Fig. 7A). One of the three
antibody-negative unvaccinated controls was also negative for
plasma viremia and appeared resistant to SIVmac251 challenge
(Fig. 4B). The absence of SIV antibodies for the remaining two
unvaccinated animals was expected because these two animals
(24078 and 30839) proved to be rapid progressors that were
euthanized at sixteen weeks after challenge due to SIV-associated
clinical illness. These findings suggested that the rise in antibody
titers detected for vaccinated animals within two weeks of chal-
lengemost likely reflected vaccine-related anamnestic responses.
By eight weeks after challenge, Env-specific antibody titers were
comparable between vaccinated and unvaccinated animals and
did not correlate with suppression of virus loads.Fig. 7. Antiviral antibody responses in animals challenged with SIVmac251. Recipro
between vaccinated and unvaccinated control animals over consecutive time points (A
SIV Env antibodies were also determined after challenge and compared between vaIncreasing Env-specific antibody avidity was observed over
the eight week time period after challenge for four of the six
vaccinated macaques and for two of three unvaccinated animals
that were antibody-positive (Fig. 7B). In contrast, the unvacci-
nated animal (24759) that exhibited a decrease in antibody
avidity between four and eight weeks after challenge, was also a
rapid progressor that was euthanized at sixteen weeks after
challenge. Otherwise, antibody avidity responses were compar-
able between vaccinatedmacaques and unvaccinated controls by
eight weeks after challenge with the exception of one vaccinated
animal (27513) that exhibited a significantly higher avidity
compared to all other animals. Overall, the magnitude of Env
antibody titer and avidity did not correlate with suppression of
virus load after challenge with pathogenic SIVmac251, although
the absence of antibody was associated with rapid disease
progression. Importantly, high SIV-specific antibody responsescal endpoint titers for plasma antibodies against native SIV Env were compared
). Reciprocal endpoint titers greater than 50 were considered positive. Avidity of
ccinated and unvaccinated control animals (B).
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single modality extremely attenuated proviral DNA vaccine that
lacked booster immunizations with viral antigens expressed from
a viral vector or as protein subunits. However, future examination
for neutralizing antibody responses will be necessary to provide a
more complete analysis of humoral responses induced by this
single modality proviral DNA vaccine.
The question remains as to whether this vif-deleted SIV
provirus plasmid functioned as a highly attenuated virus or as a
defective proviral DNA vaccine. Regardless, the results of this
study supported the “threshold hypothesis” which states that
immunization efficacy is directly related to the extent of vaccine
virus replication in vivo (Johnson et al., 1999; Ruprecht et al.,
1996). Despite the fact that vaccine-induced suppression of
challenge virus loads was insufficient to provide sustained
control of virus infection after a highly pathogenic SIVmac251
challenge, SIV/CMVΔvif plasmid immunization generated
cellular and humoral responses that were consistent with, or
actually improved over those reported for other vif-deleted
lentivirus infections and for defective SIV or SHIV proviral
DNA vaccines (Akahata et al., 2000; Gorelick et al., 2000; Liu
et al., 2006; Singh et al., 2005; Wang et al., 2000). Correlates for
vaccine-induced suppression of challenge virus loads during
acute infection were not readily apparent. However, strong SIV-
specific T cell proliferative responses, and increasing antiviral
antibody titers associated with booster immunizations, sug-
gested either persistent vaccine plasmid expression or low level
SIVΔvif replication in the host. Additional studies examining
SIV/CMVΔvif proviral DNA-inoculated macaques for tissue
reservoirs of either replicating SIVΔvif virus, or persistent SIV/
CMVΔvif plasmid, will be required to determine the origin for
the enhanced proliferative and antibody responses observed for
this vif-deleted proviral DNA vaccine. The immunogenicity,
limited suppression of challenge virus loads, and improved
median survival time associated with this vif-deleted SIV-
mac239 proviral DNA vaccine, supports further examination of
this proviral DNAvaccine as a component of multiple modality
vaccine approaches that include immunogens expressed by viral




The proviral DNA genome of a previously described SIV
vif-deletion mutant, SIVmac239Δvif (Zou and Luciw, 1996),
was modified by the replacement of the 5′ LTR with a hybrid
LTR encoding the enhancer region of the human CMV IE gene
promoter. Briefly, a hybrid LTR (CMV-LTR) encoding a 514 nt
fragment of the CMV IE promoter with enhancer elements,
nucleotides-1 to -53 of the U3 domain, and the R and U5
domains of SIVmac239 LTR, was constructed by standard
molecular cloning strategies. Next, reporter plasmids encoding
the luciferase gene directed by either the hybrid CMV-LTR
(pCMV-LTR/Luc) or the wild type SIVmac239 LTR (SIV-LTR/
Luc) were also prepared. Finally, the hybrid CMV-LTR wassubstituted for the 5′LTR of vif-deletion mutant SIVmac239Δ-
vif for construction of a SIVmac239-based provirus directed by
a potentially stronger promoter. The SIVmac239Δvif plasmid
encoding the 5′ hybrid LTR was further modified by re-
placement of the truncated nef gene encoded by the original
pMA239 provirus plasmid used to construct SIVmac239Δvif,
by insertion of a nef-containing subgenomic fragment from
SIVmac239/nef-open to produce the vaccine provirus plasmid
SIV/CMVΔvif (Fig. 1A). The structure of this vaccine provirus
was confirmed by nucleotide sequencing. Vaccine plasmid DNA
(SIV/CMVΔvif) was purified using a commercial Endofree kit
(DNA Maxi prep; Qiagen, Valencia, CA) and tested for en-
dotoxin concentrations with a commercial kit (E-Toxate, Sigma,
St. Louis, MO).
Replication assays for vaccine provirus plasmid
Replication of SIV/CMVΔvif was tested by transfection of
the SupT1 cell line, and by infection of rhesus macaque PBMC
and the macaque MM221 T cell line (provided by Ronald
Desrosiers, NewEngland PrimateResearch Center). SupT1 cells,
human embryonic kidney 293T cells, and MM221 T cells were
cultured using protocols previously described (Himathongkham
et al., 2002; Zou and Luciw, 1996). Rhesusmacaque PBMCwere
prepared by Ficoll–Hypaque density centrifugation and culti-
vated as previously described (Himathongkham et al., 2002). For
assay of replication in the SupT1 cell line, cells were transfected
with provirus plasmids (5 μg) including SIV/CMVΔvif and
SIVmac239/nef-open using electroporation protocols previously
reported (Zou and Luciw, 1996). To assess SIV/CMVΔvif
replication in MM221 cells and macaque PBMC, plasmids were
first transfected into 293T cells using Fugene 6 lipofection
reagent (Roche Molecular Biochemicals, RMB, Indianapolis,
IN) according to previously described protocols (Gemeniano
et al., 2004). Supernatants were harvested from transfected 293T
cells two days later and filtered through a 0.45 μm filter. MM221
cells and PBMC (1.5×106 cells) were washed in RPMI media
and re-suspended in 0.5ml of filtered transfected cell supernatant
for a 3 h incubation at 37 °C. Cells were next washed twice with
RPMI media and then cultivated using previously described
protocols (Himathongkham et al., 2002). Cell culture super-
natants from provirus plasmid-transfected SupT1 cells and
infected cultures of MM221 cells and macaque PBMC were
collected every three to four days and assayed by a commercial
ELISA (Coulter, Hialeah, FL) for SIV p27Gag concentrations.
DNA immunization and virus challenge
Animals used in this study included colony-bred, multi-
parous female rhesus macaques (Macaca mulatta) housed at the
California National Primate Research Center and previously
determined to be negative for antibodies to simian type D
retrovirus, SIV, HIV-2, and simian T cell leukemia virus type 1.
Tissue typing demonstrated that all animals were negative for
the major histocompatibility complex (MHC) class I allele
Mamu-A⁎01 and two animals within the vaccine group (26349
and 27513) were positive for MHC class 1 allele Mamu-B⁎17.
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and guidelines of the Institutional Animal Care and Use
committee. Physical examinations were performed at regular
time intervals for body weight, lymphadenopathy, splenome-
galy, and opportunistic infections. Clinical criteria for euthana-
sia included three or more of the following; a greater than 10%
loss of body weight, chronic diarrhea unresponsive to therapy,
persistent infections unresponsive to therapy, persistent dehy-
dration without fluid supplementation, and persistent and
marked hematologic abnormalities.
For this vaccine study, six female rhesus macaques were
inoculated with 600 μg of SIV/CMVΔvif plasmid DNA by the
intramuscular route and 400 μg of vaccine DNA by the
intradermal route to constitute a total vaccine DNA inoculum of
1 mg. At six weeks and twenty two weeks after priming im-
munization, animals received booster inoculations of SIV/
CMVΔvif plasmid DNA 1 mg; these inoculations were divided
between intramuscular and intradermal routes as described for the
initial immunization. At twenty six weeks after the priming
immunization (four weeks after the second booster inoculation),
vaccinated animals and six unvaccinated control female rhesus
macaques were challenged by the vaginal route using protocols
and a SIVmac251 virus stock previously described (Marthas
et al., 2001). Briefly, animals received two intravaginal inocula-
tions of 1 ml undiluted SIVmac251 stock containing 1×105 50%
tissue culture infectious doses (TCID50) with these two
inoculations separated by a 4 h time period over one day. Blood
samples were collected at two to four week intervals after
immunization and challenge for assessment of virus-specific
immune responses and monitoring for hematologic alterations by
complete blood cell count and CD4/CD8 subset analysis.
Virus load determination
Viral RNA concentrations in plasma were measured using a
previously described real-time reverse transcriptase (RT) Taq-
Man PCR assay with a sensitivity limit of 50–100 copies of SIV
RNA per ml of plasma (Leutenegger et al., 2001). Briefly, viral
RNA extracted from plasma with a commercial kit (QIAamp
Viral RNA Mini Kit; Qiagen, Valencia CA) was amplified in a
single step RT-PCR reaction using previously described condi-
tions and primers (SIV510f and SIV592r), TaqMan probe
(SIV535p) specific for SIVmac 251 gag, MMLV-RT (Applied
Biosystems), andAmpliTaqGoldDNA polymerase. For assay of
PBMC for proviral DNA, genomic DNA was extracted with a
commercial kit (DNeasy Blood and Tissue Kit; Qiagen) and
processed using the Applied Biosystems 6100 Nucleic Acid Prep
Station. Real-time PCR conditions for detection of cell-
associated viral DNA were previously described (Leutenegger
et al., 2001) and included assay for rhesus IL-2 as a house-
keeping gene for all reactions. All reactions were carried out in an
ABI PRISM Sequence Detector (Applied Biosystems).
T cell proliferation assay
SIV-specific T cell proliferation responses were assayed in
freshly isolated peripheral blood mononuclear cells (PBMC)using a traditional assay based on 3H-labeled thymidine incor-
poration as previously described (Abel et al., 2003; McChesney
et al., 1998). AT-2-inactivated SIV (kindly provided by Jeff
Lifson, Laboratory of Retroviral Pathogenesis, SAIC Frederick,
Bethesda, MD) in concentrations of 0.1, 1, and 10 ng per well in
a 96-well plate, served as viral antigen.
IFN-γ ELISPOT assay
Cryopreserved PBMC were tested in duplicate using a
previously described recombinant vaccinia virus (r-VV)-based
ELISPOT assay for detection of antigen-specific IFN-γ expres-
sion (Larsson et al., 1999; Shacklett et al., 2002). Recombinant
vaccinia viruses expressing SIVmac251 Gag (vAbT252), Env
(vAbT2531), Pol (vAbt258), and Nef or control r-VV (Therion
Biological, Cambridge, MA) were used as antigens. After an
overnight incubation with r-VV, PBMCwere transferred to a 96-
well ELISPOT plate (U-Cytech, Utrecht, The Netherlands)
coated with monoclonal antibody specific for macaque IFN-γ.
Spot-forming cells (SFC) were counted using a digital ELISPOT
reader (AID, Automimmun Diagnostika, Cell Technology Inc.,
Columbia MD). Results were presented as SFC per 106 cells
after subtraction of background SFC measured for control
vaccinia virus. Values greater than 50 SFC per 106 cells, were
considered positive.
Antibody assays
Plasma antibodies specific to SIVmac were assayed after
vaccination and challenged using a commercial HIV-1/HIV-2
ELISA (Genetics Systems Corporation, Redmond, Washington).
Plasma antibodies reactive to native SIV envelope proteins were
measured with a previously described ConA ELISA (Cole et al.,
1997). However, a four-fold increase in concentration of
SIVmac239 virus was used to coat ELISA plates to enhance the
sensitivity of this ELISA. Avidity of plasma antibodies to native
envelope proteins was determined by measuring resistance of
antibody-envelope glycoprotein complexes to 8Murea in a ConA
ELISA (Cole et al., 1997). The avidity index calculation was
based on the following equation: (OD450 of phosphate buffered
saline-washed wells /OD450 of urea-washed wells)×100%.
Statistics
Graphs and statistical analyses were performed using
GraphPad Prism using the Mann–Whitney-U test for compar-
ison of virus loads and CD4 T cell percentages between
vaccinated and unvaccinated control animals after challenge.
P values of b0.05 were considered significant. A survival curve
and analysis was performed using the Kaplan–Meier method
(GraphPad Prism).
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